SCHEMBL3068612

SCHEMBL3068612

Fc1c(C(c2ccncc2)c2cnc[nH]2)cccc1C(F)(F)F

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 4/20 0.43
CYP1A2 P05177 2/20 0.43
CYP3A4 P08684 2/20 0.43
CYP2D6 P10635 2/20 0.43
CYP2C19 P33261 2/20 0.43
HRH1 P35367 1/20 0.43
HRH4 Q9H3N8 1/20 0.43
IDO1 P14902 1/20 0.38
TDO2 P48775 1/20 0.38
ADRA2A P08913 10/20 0.37
ADRA2B P18089 9/20 0.37
ADRA2C P18825 9/20 0.37
ADRA1A P35348 7/20 0.37
ADRA1B P35368 6/20 0.37
ADRA1D P25100 5/20 0.37
KCNH2 Q12809 1/20 0.37
TP53 P04637 1/20 0.37
CYP2C9 P11712 1/20 0.37
TSHR P16473 1/20 0.37
SLC6A2 P23975 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1639638 0.91 IDO1 (0.47) HRH3CYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL3074242 0.88 HRH3 (0.46) HRH3CYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL3062666 0.84 ADRA2A (0.40) HRH3CYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL3072215 0.83 HRH3 (0.47) HRH3CYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL3068900 0.82 ADRA2A (0.39) HRH3CYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL13089037 0.79 IDO1 (0.37) IDO1TDO2SLC6A2
SCHEMBL3055369 0.79 CYP19A1 (0.44) HRH3CYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL3064400 0.77 ADRA2A (0.48) HRH3CYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL1638482 0.75 CYP19A1 (0.46) CYP1A2CYP3A4CYP2D6CYP2C19ADRA2A
SCHEMBL3062592 0.74 ADRA2A (0.40) HRH3CYP1A2CYP3A4CYP2D6CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2155715-B1 ((PHENYL)IMIDAZOLYL)METHYLHETEROARYL COMPOUNDS ALLERGAN INC (US) 2013-03-13 EP disclosed
US-20100273814-A1 ((PHENYL)IMIDAZOLYL)METHYLHETEROARYL COMPOUNDS SINHA SANTOSH C 2010-10-28 US disclosed
EP-2155715-A1 ((PHENYL)IMIDAZOLYL)METHYLHETEROARYL COMPOUNDS ALLERGAN, INC. (US) 2010-02-24 EP disclosed
WO-2008141312-A1 ((PHENYL)IMIDAZOLYL)METHYLHETEROARYL COMPOUNDS ALLERGAN, INC. (US) 2008-11-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100273814-A1 ((PHENYL)IMIDAZOLYL)METHYLHETEROARYL COMPOUNDS CYP11B2, TPMT, COXFA4L2 HRH3 579/4885CYP1A2 290/4885CYP3A4 65/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.